ALUMIS INC.(ALMS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

ALUMIS INC. (ALMS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALMS at 7.1/100 on a 32-signal composite quality model, placing it at rank #2,948 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.7) and profitability (0.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ALUMIS INC. reports quarterly revenue of $1.7M, net income of $-142.2M, free cash flow of $-81.7M. Top institutional holders of ALMS by reported 13-F value include AyurMaya Capital Management Company, BlackRock, FMR, based on the most recent SEC filings. ALMS trades on the Nasdaq exchange and files with the SEC under CIK 1847367. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALMS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALUMIS INC. directly from SEC EDGAR.

AI Quality Score

7.1/100

AI Rank

#2,948

Revenue

$1.7M

Net Income

$-142.2M

Free Cash Flow

$-81.7M

ALMS key financials by period

ALUMIS INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$24.1M$-243.3M

Institutions holding ALMS

Institutional investors reporting a position in ALUMIS INC. on SEC Form 13F.
InstitutionSharesValueReported
AyurMaya Capital Management Company15,139,707$426.0M2026-06-30
BlackRock8,218,151$231.3M2026-06-30
FMR6,769,170$190.5M2026-06-30
Deep Track Capital6,348,558$178.6M2026-06-30
Samsara BioCapital6,345,219$178.6M2026-06-30
Foresite Capital Management V5,896,995$165.9M2026-06-30
PRICE T ROWE ASSOCIATES5,199,838$146.3M2026-06-30
venBio Partners4,528,408$127.4M2026-06-30
Foresite Capital Management VI4,247,670$119.5M2026-06-30
VANGUARD CAPITAL MANAGEMENT4,215,703$118.6M2026-06-30
ALMS

ALUMIS INC.

ALMS
NasdaqMid CapHealthcare

13F Pro Quality Score

7.1/100

Rank #2,948 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

2.1/100

Profitability

0.9/100

Balance Sheet

1.9/100

Earnings Quality

22.0/100

Free Cash Flow

0.7/100

Institutional Flow

70.7/100

Revenue Scale

1.8/100

Dilution Risk

1.9/100

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$1.66M

Net Income

Q2 2026
EDGAR

$-142.22M

EPS (Diluted)

Q2 2026
EDGAR

$-1.11

Free Cash Flow

Q2 2026
EDGAR

$-81.74M

Top Institutional Holders

as of Q2 2026
$3.36B total

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…